OakChart

Compass Therapeutics Inc

CMPXHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 8:39 AM ET

0.8700+0.0320 (3.82%)
2026-11-11 14:59 CET
Market cap
150.91 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-86.36 USD m
Free cash flow, TTM
-61.94 USD m
EPS diluted, TTM
-0.46
P/E
-
Compare

Price

CMPX against its 20, 50 and 200-day averages
2050200miss
1.002.003.004.0013.6M27.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CMPXclose 0.8720-day 0.7950-day 1.20200-day 2.980.87

87.4% under 6.88 on 3 Feb 2026. Last 15 sessions, 33.5% high to low

Profile

CMPX
52-week range, 3% of the way up
0.676.88

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

IndexRUT
Employees39
IPOApr 05, 2021
Beta1.05
ATR, 14d0.07
Rel volume0.06
Short float31.68%
Insider own28.51%
Inst own74.24%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap156.67M
Enterprise Value2.84M
Income-86.36M
Sales0.00M
Book/sh0.79
Cash/sh0.91
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees39
IPOApr 05, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.10
P/C0.96
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio6.79
Current Ratio6.79
Debt/Eq0.06
LT Debt/Eq0.05
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.46
EPS next Y-0.59
EPS next Q-0.15
EPS this Y-24.70%
EPS next Y-13.58%
EPS next 5Y-9.02%
EPS past 3/5Y-4.18% 5.72%
Sales past 3/5Y- -
EPS Y/Y TTM-1.27%
Sales Y/Y TTM-100.00%
EPS Q/Q-72.19%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.-18.67% -

Ownership

Insider Own28.51%
Insider Trans0.04%
Inst Own74.24%
Inst Trans-1.61%
ROA-42.57%
ROE-49.04%
ROIC-57.52%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA209.63%
SMA50-27.52%
SMA200-70.83%
Trades-

Technical

Shs Outstand180.09M
Shs Float128.74M
Short Float31.68%
Short Ratio10.10
Short Interest40.79M
52W High6.88 -87.35%
52W Low0.67 29.58%
Volatility9.85% 7.73%
ATR (14)0.07
RSI (14)46.10
Beta1.05
Rel Volume0.06
Avg Volume4.04M
Volume12,320

Performance

Perf Week14.07%
Perf Month1.52%
Perf Quarter-61.50%
Perf Half Y-55.84%
Perf YTD-83.80%
Perf Year-81.21%
Perf 3Y-43.87%
Perf 5Y-75.77%
Perf 10Y-
Recom1.40
Target Price5.33
Prev Close0.84
Price0.87
Change %3.82%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 23, 2026DowngradeWWedbushOutperform → Neutral$1+14.9%
Jul 01, 2026ResumedLLadenburg ThalmannBuy$5+474.7%
Apr 28, 2026DowngradeRRaymond JamesOutperform → Mkt Perform
Feb 13, 2026InitiatedCCraig HallumBuy$15+1,624.1%
Jan 05, 2026InitiatedWWilliam BlairOutperform
Dec 03, 2025InitiatedCCitizens JMPMkt Outperform$10+1,049.4%
Dec 03, 2025InitiatedCCantor FitzgeraldOverweight
Dec 03, 2025InitiatedCCanaccord GenuityBuy$10+1,049.4%
Jul 01, 2025ResumedRRaymond JamesOutperform$9+934.5%
Apr 02, 2025UpgradeLLeerink PartnersMarket Perform → Outperform$6+589.7%

Peers

Mkt cap
TickerCompanyMkt cap
CBIOCrescent Biopharma Inc517.04M
ZYMEZymeworks BC Inc2.22B
SMMTSummit Therapeutics Inc14.32B
TILInstil Bio Inc43.07M
JAZZJazz Pharmaceuticals plc15.73B
BNTXBioNTech SE ADR21.76B
MGNXMacrogenics Inc154.15M
CTMXCytomX Therapeutics Inc433.83M
INCYIncyte Corp23.64B
XNCRXencor Inc2.96B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lerner NeilChief Accounting OfficerOct 01 '26Buy0.9220,00018,400420,000Oct 02 08:00 AM
Lerner NeilChief Accounting OfficerSep 24 '26Buy1.142,5002,850400,000Sep 25 08:01 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B

News

latest 14 of 206
  • Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +10.29%
  • Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting (GlobeNewswire) +10.84%
  • Compass Therapeutics to Participate in Upcoming November Investor Events (GlobeNewswire)
  • Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 (GlobeNewswire)
  • Emergent BioSolutions stock falls as CFO plans retirement (Investing.com)
  • Loading…
  • Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls (The Fly) -5.65%
  • Compass Therapeutics FDA Setback Raises Concerns On Wall Street H.C. Wainwright Calls Tovecimig Filing Strategy Risky (Stocktwits)
  • CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug Wedbush Sees Another 19% Downside (Stocktwits) -31.87%
  • CMPX Stock Crashes To Over 2-Year Lows Why FDA Wants Another Cancer Therapy Trial Before Key Marketing Filing (Stocktwits)
  • Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback (GlobeNewswire)
  • Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire) +5.29%
  • Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.150-0.126-0.1500.000.0015
2026Q22026-08-06-0.130-0.111-0.1350.00-0.6015
2026Q12026-05-05-0.100-0.098-0.0980.00-0.8215
2025Q42026-03-05-0.090-0.094-0.0850.000.0016
2025Q32025-11-05-0.080-0.139-0.0850.000.0011
2025Q22025-08-11-0.140-0.124-0.1440.000.0010
2025Q12025-05-08-0.120-0.110-0.1200.000.009
2024Q42025-02-27-0.110-0.098-0.1090.000.0010
2024Q32024-11-12-0.080-0.113-0.0760.000.007
2024Q22024-08-12-0.100-0.096-0.0950.880.007
2024Q12024-05-13-0.080-0.113-0.0790.000.007
2023Q42024-03-21-0.110-0.094-0.1050.000.007
2023Q32023-11-09-0.080-0.107-0.0780.000.007
2023Q22023-08-03-0.090-0.081-0.0890.000.007
2023Q12023-05-04-0.060-0.106-0.0620.000.008
2022Q42023-03-15-0.100-0.111-0.1000.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1.310-1.254-0.8150.000.00
2022FY-0.370-0.384-0.3730.000.00
2023FY-0.330-0.333-0.3350.000.00
2024FY-0.360-0.351-0.3590.870.89
2025FY-0.420-0.431-0.4200.000.00
2026FY--0.524--0.00
2027FY--0.595--4.62
2028FY--0.544--41.76
2029FY--0.342--110.27
2030FY--0.016--186.26

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0912000.000.000.00
2026Q4S2026-10-2012000.000.000.00
2026Q4S2026-08-1412100.000.000.00
2026Q4S2026-08-1311100.000.000.00
2026Q4S2026-08-0612100.000.000.00
2026Q4S2026-07-191200-1.80-21.600.00
2026Q4S2026-07-081201-1.80-21.600.00
2026Q4S2026-06-301202-1.80-21.600.00
2026Q4S2026-05-211102-1.96-21.600.00
2026Q4S2026-05-201202-0.88-21.6011.00
2026Q4S2026-05-051203-0.88-21.6011.00
2026Q4S2026-04-2412020.920.0011.00
2026Q4S2026-03-1212013.030.0025.40
2026Q4S2026-03-0613012.800.0025.40

Estimate history

EPS, annual-0.735-0.01-0.566-0.815-0.373-0.335-0.359-0.422-0.4634
Period20182019202020212022202320242025TTM
EPS, quarterly-0.076-0.109-0.12-0.144-0.085-0.085-0.098-0.135-0.146
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000.8500
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual52.112552.112100.832126.302127.668137.82178.324180.088
Period20182019202020212022202320242025MRQ
Shares, quarterly137.589137.82138.282138.282177.572178.324180.088180.088180.088
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY
Total Revenue0.000.000.850.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.501.471.751.891.901.622.400.002.12
Gross Profit-1.50-1.47-0.90-1.89-1.90-1.62-2.400.00-2.12
Selling, General and Administrative Excl. Other92.5771.3755.7248.4739.7529.6425.410.0331.93
Research and Development68.6055.6941.7537.4229.2119.7714.90-22.45
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-94.07-72.84-56.62-50.36-41.66-31.26-27.81-0.03-34.05
Interest Expense0.000.000.000.000.000.370.910.011.23
Unusual Expense0.000.000.000.000.0050.620.56-0.10
Net Income Before Taxes-86.36-66.49-49.38-42.49-39.23-82.18-29.47-0.04-34.65
Income Taxes0.000.000.000.000.000.000.030.000.09
Consolidated Net Income-86.36-66.49-49.38-42.49-39.23-82.18-29.50-0.04-34.74
Net Income From Continuing Operations-86.36-66.49-49.38-42.49-39.23-82.18-29.50-0.04-34.74
Net Income-86.36-66.49-49.38-42.49-39.23-82.18-29.50-0.04-34.74
EPS (Recurring)-0.46-0.42-0.36-0.33-0.37-0.46-0.56-0.01-0.67
EPS (Basic, Before Extraordinaries)-0.46-0.42-0.36-0.33-0.37-0.81-0.57-0.01-0.67
EPS (Diluted)-0.46-0.42-0.36-0.33-0.37-0.81-0.57-0.01-0.67
EBITDA-92.57-71.37-54.87-48.47-39.75-29.64-25.41-0.03-31.93
Non-Operating Income (Expense)7.716.357.257.872.430.07-0.190.000.73
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense15.738.378.566.125.334.032.93-0.67
Price To Sales Ratio--234.36------
Gross Margin---106.24------
Operating Margin---6,661.76------
Net Margin---5,808.82------
Shares Outstanding180.09178.32137.82127.67126.30100.8352.115.0052.11
Market Capitalization150.91150.91199.50198.88634.74310.76294.09--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.390.380.370.370.370.370.360.36
Gross Profit-0.39-0.38-0.37-0.37-0.37-0.37-0.36-0.36
Selling, General and Administrative Excl. Other28.4126.6019.9317.6215.4520.7017.6016.21
Research and Development22.0119.5513.3813.6612.8116.3212.9112.89
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-28.80-26.98-20.30-17.99-15.82-21.07-17.97-16.57
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-27.17-25.15-18.32-15.72-14.26-19.88-16.63-15.03
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-27.17-25.15-18.32-15.72-14.26-19.88-16.63-15.03
Net Income From Continuing Operations-27.17-25.15-18.32-15.72-14.26-19.88-16.63-15.03
Net Income-27.17-25.15-18.32-15.72-14.26-19.88-16.63-15.03
EPS (Recurring)-0.15-0.13-0.10-0.09-0.08-0.14-0.12-0.11
EPS (Basic, Before Extraordinaries)-0.15-0.13-0.10-0.09-0.08-0.14-0.12-0.11
EPS (Diluted)-0.15-0.13-0.10-0.09-0.08-0.14-0.12-0.11
EBITDA-28.41-26.60-19.93-17.62-15.45-20.70-17.60-16.21
Non-Operating Income (Expense)1.631.821.982.271.561.191.331.54
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.014.825.071.821.242.792.512.24
Price To Sales Ratio------309.00235.10
Shares Outstanding180.09180.09180.09178.32177.57138.28138.28137.82
Market Capitalization150.91394.39952.67955.12600.50359.54262.74199.50

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY2018FY
Cash & Short Term Investments208.91126.72152.46186.61144.5147.080.0025.3057.51
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.916.031.428.182.593.130.000.941.37
Total Current Assets209.82132.75153.88194.79147.1050.200.0026.2458.88
Net Property, Plant & Equipment9.207.082.674.536.331.130.003.755.37
Total Investments and Advances0.570.000.000.000.000.260.000.260.26
Intangible Assets0.00-----0.00--
Deferred Tax Assets2.56--------
Other Assets0.000.570.320.320.320.320.000.130.12
Total Assets222.15140.40156.88199.65153.7651.910.0030.3864.62
Short Term Debt Incl. Current Port. of LT Debt1.000.341.201.100.997.470.105.583.69
Accounts Payable1.582.254.093.380.871.060.000.631.73
Other Current Liabilities11.386.292.5111.698.781.570.013.623.05
Total Current Liabilities13.978.877.8016.1710.6310.100.119.828.46
Long Term Debt8.836.300.541.843.051.870.00139.16140.93
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities2.56--------
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities25.3615.178.3418.0113.6811.970.11148.98149.40
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity196.79125.23148.54181.64140.0839.95-0.11-118.60-84.77
Total Shareholders Equity196.79125.23148.54181.64140.0839.95-0.11-118.60-84.77
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity196.79125.23148.54181.64140.0839.95-0.11-118.60-84.77
Total Liabilities & Stockholders Equity222.15140.40156.88199.65153.7651.910.0030.3864.62
Book Value Per Share1.100.911.161.441.390.77-0.02-2.28-1.63
Tangible Book Value Per Share1.100.911.161.441.390.77-0.02-2.28-1.63
Full-Time Employees393532262431---
Price to Book Ratio1.061.441.244.382.287.76---
Return on Assets-36.68-33.22-23.84-22.20-79.92-71.70-0.12-73.14-
Return on Equity-41.29-36.07-25.74-24.38-91.30----
Return on Invested Capital-32.34-37.54-28.51-21.38-57.42-70.55--168.99-68.17
Quick Ratio15.0214.9619.7312.0513.844.970.032.676.96
Current Ratio15.0214.9619.7312.0513.844.970.032.676.96

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2019FY
Net Income-86.36-66.49-49.38-42.49-39.23-82.18-29.50-0.04-34.74
Depreciation1.501.471.751.891.901.622.40-2.12
Other Funds (Non Cash)14.216.706.912.894.4654.654.940.001.14
Funds from Operations-70.65-58.32-40.71-37.71-32.86-25.91-22.15-0.04-31.48
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital9.079.18-4.14-2.91-1.266.25-4.650.01-0.26
Cash from Operating Activities-61.58-49.14-44.85-40.62-34.12-19.67-26.80-0.03-31.74
Capital Expenditures-0.36-0.03-0.04-0.03-0.21-1.89-0.110.00-0.47
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.180.120.140.000.00
Purchase or Sale of Investments52.77-93.2846.8227.00-151.160.000.000.000.00
Purchase of Investments-118.45-194.56-88.16-155.42-200.120.000.000.000.00
Sale Or Maturity of Investments171.22101.28134.97182.4148.950.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities52.41-93.3146.7726.96-151.20-1.770.040.00-0.47
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.13130.6417.573.0975.76127.9954.160.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.13130.6417.573.0975.76127.9954.160.000.00
Proceedsfrom Stock Options3.85129.3617.573.0375.74127.9954.160.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.00-9.38-5.620.030.00
Change in Long Term Debt0.000.000.000.000.00-9.38-5.620.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-9.38-5.620.000.00
Net Financing Active Other Cash Flow-0.70-1.03-0.23-0.160.000.000.000.000.00
Other Financing Activities Uses-0.70-1.03-0.23-0.160.000.000.000.000.00
Cash from Financing Activities4.43129.6117.342.9475.76118.6148.540.030.00
Net Change in Cash-4.74-12.8419.25-10.72-109.5797.1721.77-0.00-32.21
Free Cash Flow-61.94-49.17-44.90-40.65-34.34-21.55-26.91-0.03-32.21
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments163.06179.88194.69208.91219.90100.95
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.441.011.000.911.235.25
Total Current Assets165.50180.89195.69209.82221.12106.19
Net Property, Plant & Equipment8.438.718.919.209.579.94
Total Investments and Advances0.570.570.570.570.570.57
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets---2.56--
Other Assets0.000.000.000.000.000.00
Total Assets174.50190.17205.17222.15231.26116.70
Short Term Debt Incl. Current Port. of LT Debt1.671.641.371.000.630.27
Accounts Payable6.322.910.911.583.102.60
Other Current Liabilities16.3811.598.0011.388.6810.99
Total Current Liabilities24.3716.1310.2813.9712.4113.86
Long Term Debt7.568.008.428.839.239.63
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---2.56--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities31.9324.1218.7025.3621.6523.49
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity142.57166.05186.47196.79209.6193.21
Total Shareholders Equity142.57166.05186.47196.79209.6193.21
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity142.57166.05186.47196.79209.6193.21
Total Liabilities & Stockholders Equity174.50190.17205.17222.15231.26116.70
Book Value Per Share0.790.921.041.101.180.67
Tangible Book Value Per Share0.790.921.041.101.180.67
Full-Time Employees---39--
Price to Book Ratio1.062.124.794.555.193.26
Return on Assets-42.57-47.87-40.50-36.68-34.60-45.55
Return on Equity-49.04-56.66-45.95-41.29-37.82-51.84
Return on Invested Capital-18.10-14.45-9.40-7.64-6.52-19.33
Quick Ratio6.7911.2219.0415.0217.827.66
Current Ratio6.7911.2219.0415.0217.827.66

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-27.17-25.15-18.32-15.72-14.26-19.88
Depreciation0.390.380.370.370.370.37
Other Funds (Non Cash)4.094.624.870.630.862.66
Funds from Operations-22.69-20.15-13.08-14.72-13.03-16.85
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital6.385.42-4.191.462.185.02
Cash from Operating Activities-16.32-14.74-17.27-13.25-10.85-11.83
Capital Expenditures-0.11-0.18-0.080.00-0.010.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments22.44-4.8038.51-3.38-95.15-6.36
Purchase of Investments-5.54-40.62-44.81-27.48-109.08-33.17
Sale Or Maturity of Investments27.9835.8183.3324.1013.9326.81
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities22.33-4.9838.43-3.38-95.16-6.36
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.003.851.27129.360.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.003.851.27129.360.00
Proceedsfrom Stock Options0.000.003.850.00129.360.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.49-0.210.000.00
Other Financing Activities Uses0.000.00-0.49-0.210.000.00
Cash from Financing Activities0.000.003.371.06129.360.00
Net Change in Cash6.02-19.7124.52-15.5723.36-18.19
Free Cash Flow-16.42-14.91-17.35-13.25-10.86-11.83

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 850.00K
United States2024: 850.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3031.68%40.8M128.7M4.25M
2026-10-1532.50%41.8M128.7M4.26M
2026-09-3029.56%40.4M136.5M3.41M
2026-09-1530.50%41.6M136.6M2.99M
2026-08-3129.87%40.8M136.6M3.13M
2026-08-1429.43%40.2M136.6M3.57M
2026-07-3131.13%39.9M128.1M4.19M
2026-07-1530.68%39.3M128.1M8.00M
2026-06-3028.99%37.1M128.1M7.98M
2026-06-1525.38%32.5M128.1M7.55M
2026-05-2925.97%33.3M128.1M7.38M
2026-05-1525.12%31.0M123.5M6.93M
2026-04-3025.17%30.4M120.9M6.00M
2026-04-1521.60%26.1M120.7M2.21M
2026-03-3120.70%26.1M126.2M2.25M
2026-03-1318.87%23.8M126.2M2.20M
2026-02-2718.23%23.0M126.2M2.14M
2026-02-1317.94%22.4M124.6M2.16M
2026-01-3017.72%21.9M123.8M2.20M
2026-01-1518.58%23.0M123.8M2.12M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.050.850.4419.4644.000.000.869-0.0060.000
call1.000.000.050.041.8728,29920.000.341-0.0050.001
call1.500.000.050.053.3042780.000.231-0.0070.000
call2.000.000.050.034.3916,3450.000.200-0.0090.000
call3.000.000.050.025.30423,6610.000.174-0.0090.000
call4.000.000.050.046.0251120.000.162-0.0100.000
call5.000.000.050.056.8713,7890.000.155-0.0110.000
call6.000.000.050.216.97220.000.000.149-0.0110.000
call7.000.000.500.057.3144.000.000.146-0.0110.000
call8.000.000.750.277.9708.000.000.143-0.0130.000
call9.000.000.950.008.2320.000.000.140-0.0130.000
call10.000.001.200.008.4630.000.000.138-0.0130.000
call11.000.001.700.208.6691.000.000.137-0.0130.000
call12.000.001.200.008.8540.000.000.135-0.0130.000
call13.000.001.450.009.0230.000.000.134-0.0140.000
put0.500.000.050.033.9920.000.00-0.131-0.0060.000
put1.000.100.200.191.6931,2266.00-0.659-0.0050.001
put1.500.301.000.809.0241410.00-0.769-0.0070.000
put2.000.602.951.220.00090.001.00-0.800-0.0080.000
put3.001.802.552.1712.2753.001.00-0.827-0.0100.000
put4.001.055.203.260.0000.000.00-0.838-0.0100.000
put5.002.056.204.140.0000.000.00-0.845-0.0110.000
put6.004.505.705.3217.4562.000.00-0.851-0.0110.000
put7.005.406.906.1424.7510.000.00-0.854-0.0120.000
put8.006.407.907.2525.0940.000.00-0.857-0.0120.000
put9.007.408.908.2525.3991.000.00-0.860-0.0120.000
put10.007.1011.209.300.0001.000.00-0.862-0.0120.000
put11.008.2010.4010.2013.0863.002.00-0.863-0.0120.000
put12.009.1013.2011.250.0000.000.00-0.865-0.0120.000
put13.0010.2014.1012.270.0001.000.00-0.866-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-228-KCurrent report2026-09-22SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-018-KCurrent report2026-07-01SEC
2026-06-238-KCurrent report2026-06-22SEC
2026-06-118-KCurrent report2026-06-10SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-058-KCurrent report2026-05-05SEC
2026-04-304/A2026-04-29SEC
2026-04-304/A2026-04-29SEC
2026-04-294Statement of changes in beneficial ownership of securities2026-04-29SEC
2026-04-294Statement of changes in beneficial ownership of securities2026-04-29SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-10SEC
2026-04-278-KCurrent report2026-04-27SEC
2026-03-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-0510-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-058-KCurrent report2026-03-05SEC
2026-02-13SCHEDULE 13G/ASEC
2026-02-104Statement of changes in beneficial ownership of securities2026-02-08SEC
2026-01-21SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1018.40K100
2026-092.85K100
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
TANG CAPITAL MANAGEMENT LLC9.99%
ORBIMED ADVISORS LLC8.45%
MONTANOVA CAPITAL, LLC7.83%
BlackRock, Inc.6.26%
STATE STREET CORP5.53%
Enavate Sciences GP, LLC4.32%
Vivo Capital, LLC4.31%
VANGUARD CAPITAL MANAGEMENT LLC3.40%
Palo Alto Investors LP3.24%
MILLENNIUM MANAGEMENT LLC2.62%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.80%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.33%
iShares Russell 2000 ETF1.92%
VANGUARD EXTENDED MARKET INDEX FUND1.00%
Fidelity Small Cap Index Fund0.79%
iShares Russell 2000 Value ETF0.67%
Fidelity Enhanced Small Cap Core ETF0.62%
VANGUARD EXPLORER FUND0.53%
Fidelity Extended Market Index Fund0.46%
SMALL COMPANY GROWTH PORTFOLIO0.43%

OakChart. CMPX. Cached 15 minutes.